Prevalence of claudin 18.2 (CLDN18.2) and the association of biomarkers with clinical activity in patients with gastric or gastroesophageal adenocarcinoma (G/GEJa) treated with zolbetuximab.

被引：0

作者：

Moran, Diarmuid Martin

Guerrero, Abraham

Ueno, Yoko

Park, Jung Wook

Pavese, Janet

Kaneko, Yuichiro

Matsangou, Maria

Shitara, Kohei

机构：

[1] Astellas Pharma Global Dev Inc, Northbrook, IL USA

[2] Astellas Pharma Inc, Northbrook, IL USA

[3] Astellas Pharma Inc, Tokyo, IL, Japan

[4] Astellas Pharma US Inc, Northbrook, IL USA

[5] Dept Natl Canc Ctr Hosp East, Gastrointestinal Oncol, Chiba, Japan

来源：

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

466

引用

页码：466 / 466

页数：1